Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Far ...

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025. Red Cat, together with its subsidiaries, provides various products, services, and solutions to the U.S. drone industry. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NWTN Inc. and its officers or directors [1] Group 1: Company Developments - On May 28, 2025, NWTN disclosed that it received a determination notice from Nasdaq regarding the delisting of its securities [3] - Following the delisting news, NWTN's stock price dropped by $0.72 per share, representing a 32% decline, closing at $1.53 per share on May 30, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4]

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][6]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][6]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly about its quarterly dividend [6]. - The company allegedly misrepresented its commitment to dividends while internally prioritizing debt reduction [6]. - Following the acquisition of Dermavant Sciences Ltd., Organon reduced its quarterly dividend by over 70% [6].

Core Viewpoint - A securities class action lawsuit has been filed against Krispy Kreme, alleging false or misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand [1][6]. Allegations - Krispy Kreme allegedly made false or misleading statements and/or failed to disclose a significant decline in demand for products at McDonald's after the initial marketing launch [6]. - This decline led to lower average sales per location [6]. - The partnership with McDonald's was reportedly not profitable [6]. - These issues posed risks to the continuation of the partnership [6]. - As a result, Krispy Kreme would pause expanding to new McDonald's locations [6]. Legal Context - The law firm Wolf Haldenstein, with over 125 years of experience in securities litigation, is representing the investors affected by these alleged misrepresentations [4]. - Investors who purchased Krispy Kreme securities during the specified class period have until July 15, 2025, to request to be appointed as Lead Plaintiff [2].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were countered by a new debt reduction strategy that resulted in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon reportedly prioritized debt reduction over dividend payouts [4]. Financial Impact - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives, following disappointing financial results and stock price decline [1][3]. Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which was $13.14 million below consensus estimates, marking a 30.1% decline year-over-year [3]. - The company attributed the revenue shortfall to delays in U.S. government contract awards, linked to leadership transitions at agencies such as NASA and the Space Development Agency, as well as changing budget priorities under the Trump administration [3]. Stock Market Reaction - Following the release of the financial results, Redwire's stock price decreased by $0.75, or 6.63%, closing at $10.56 per share on May 12, 2025 [4].

Core Viewpoint - The DoubleVerify Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misleading statements and undisclosed risks impacting the company's stock performance during the specified class period [1][3]. Company Allegations - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited, affecting its competitive position [3]. - It is alleged that the development of technology for closed platforms was more expensive and time-consuming than disclosed, limiting DoubleVerify's ability to monetize its Activation Services [3]. - Competitors were reportedly better positioned to incorporate AI into their offerings, which negatively impacted DoubleVerify's profits and competitive edge [3]. - The company is accused of systematically overbilling customers for ad impressions served to bots, and its risk disclosures were misleading, presenting adverse facts as mere possibilities [3]. Stock Performance Impact - Following a lower revenue growth expectation announcement on February 28, 2024, DoubleVerify's stock price fell over 21% [4]. - On May 7, 2024, after cutting its full-year 2024 revenue outlook due to reduced customer ad spending, the stock price dropped nearly 39% [5]. - A report on February 27, 2025, detailing lower-than-expected sales and earnings due to reduced customer spending led to a further stock price decline of more than 36% [6]. Legal Process - Investors who purchased DoubleVerify common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of misleading statements and undisclosed costs that negatively impacted the company's financial performance [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Canopy Growth and its executives violated federal securities laws by making false statements and failing to disclose significant costs related to the Claybourne product launch and Storz & Bickel vaporizer devices [4]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs associated with the Claybourne infused pre-roll launch and increased indirect costs related to vaporizer devices [5]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [5]. Group 2: Market Reaction - Following the announcement of the financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [7]. Group 3: Legal Proceedings - Investors who purchased Canopy securities between May 30, 2024, and February 6, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and the June 3, 2025, deadline to seek lead plaintiff status in the class action [2][8].